{
    "nct_id": "NCT03671811",
    "official_title": "Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy",
    "inclusion_criteria": "* Documented informed consent of the participant and/or legally authorized representative\n* Willing to undergo an intraoperative biopsy/or standard of care tissue collection during surgery, following completion of treatment with MA +/- PTE\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2\n* Histologically confirmed EC or complex atypical hyperplasia of the endometrium\n* Candidate for a total hysterectomy with or without bilateral salpingo-oophorectomy\n* About to initiate preoperative window period, with planned hysterectomy scheduled\n* Platelets >= 100,000/mm^3\n\n  * NOTE: Platelet transfusions are not permitted within 14 days of platelet assessment unless cytopenia is secondary to disease involvement\n* Total bilirubin =< 1.5 X upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) =< 1.5 x ULN\n* Alanine aminotransferase (ALT) =< 1.5 x ULN\n* Creatinine clearance of >= 60 mL/min per 24 hour urine test or the Cockcroft-Gault formula\n* Women of childbearing potential: negative urine or serum pregnancy test in premenopausal women. Postmenopausal women do not need to undergo a pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pterostilbene supplements within 30 days prior to day 1 of protocol therapy\n* Any of the following phytochemical-based supplements within 30 days prior to day 1 of protocol therapy: resveratrol, genistein, and quercetin\n* Chemotherapy for EC\n* Allergic reaction/hypersensitivity to similar agents, excipients\n* Unstable cardiac disease as defined by one of the following:\n\n  * Cardiac events such as myocardial infarction (MI) within the past 6 months\n  * NYHA (New York Heart Association) heart failure class III-IV\n  * Uncontrolled atrial fibrillation or hypertensive emergency/urgency (defined as systolic blood pressure >= 180 mmHg and/or diastolic blood pressure >= 120 mmHg)\n* Active or history of recent thromboembolism or stroke, within the past 6 months\n* Cushing's syndrome\n* Acute infection requiring systemic (intravenous) treatment\n* Known history of human immunodeficiency virus (HIV) infection\n* Known active hepatitis B or C infection\n* Inability to swallow tablets/capsules\n* Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc\n* Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)",
    "miscellaneous_criteria": ""
}